Mereo BioPharma
MREO
18 hedge funds and large institutions have $4.39M invested in Mereo BioPharma in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.88% more ownership
Funds ownership: 0% → 1.88% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$3.04M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$2.29M |
| 3 |
Renaissance Technologies
New York
|
+$857K |
| 4 |
PA
Perceptive Advisors
New York
|
+$785K |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
+$337K |
Top Sellers
MREO Hedge Fund Activity: Q2 2019 in Review
18 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2019, worth a combined $4.39M.
Buyers outnumbered sellers: 18 funds opened new MREO positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Primecap Management, opening a new position worth an estimated $3.04M.
- 18 institutional investors held Mereo BioPharma (MREO) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $4.39M of Mereo BioPharma stock for Q2 2019.
- 18 funds opened new Mereo BioPharma positions in Q2 2019 and 0 closed out, a net change of +18 holders.
- The largest Mereo BioPharma buyer in Q2 2019 was Primecap Management, an estimated $3.04M added.
Based on aggregated 13F filings for Q2 2019.